Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review)

Placenta

Volumn 32, Issue SUPPL. 4, 2011, Pages

  McGuirk, J P ^a   Weiss, M L ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

Allogeneic transplant; Bone marrow transplantation; Immune modulation; Leukemia; Mesenchymal stromal cells; Wharton's jelly

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CELL THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; MESENCHYME CELL; MUCOSA; PRIORITY JOURNAL; STROMA CELL; WHARTON JELLY;

CLINICAL TRIALS AS TOPIC; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFANT, NEWBORN; MESENCHYMAL STEM CELLS; PREGNANCY; STEM CELL TRANSPLANTATION; UMBILICAL CORD; WHARTON JELLY;

EID: 80052461617     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2011.04.013     Document Type: Article

References (67)

1. T.A. Gooley, J.W. Chien, S.A. Pergam, S. Hingorani, M.L. Sorror, and M. Boeckh Reduced mortality after allogeneic hematopoietic-cell transplantation N Engl J Med 363 2010 2091 2101
2. A. Bacigalupo Management of acute graft-versus-host disease Br J Haematol 137 2007 87 98 (Pubitemid 46474711)
3. S.J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood 105 2005 4200 4206 (Pubitemid 40720763)
4. J.E. Wagner, J.S. Thompson, S.L. Carter, and N.A. Kernan Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial Lancet 366 2005 733 741 (Pubitemid 41207235)
5. J. Pidala, and C. Anasetti Glucocorticoid-refractory acute graft-versus-host disease Biol Blood Marrow Transplant 16 2010 1504 1518
6. D. Wolff, A. Gerbitz, F. Ayuk, A. Kiani, G.C. Hildebrandt, and G.B. Vogelsang Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD Biol Blood Marrow Transplant 16 2010 1611 1628
7. H. Glucksberg, R. Storb, A. Fefer, C.D. Buckner, P.E. Neiman, and R.A. Clift Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 1974 295 304
8. A. Gratwohl, J. Hermans, J. Apperley, W. Arcese, A. Bacigalupo, and G. Bandini Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation Blood 86 1995 813 818
9. S.Z. Pavletic, P. Martin, S.J. Lee, S. Mitchell, D. Jacobsohn, and E.W. Cowen Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of health consensus development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report Biol Blood Marrow Transplant 12 2006 252 266 (Pubitemid 43273710)
10. M. Arora, J.P. Klein, J.H. Antin, B.J. Bolwell, M. Boyiadzis, and J. Cahn Chronic graft-versus-host disease risk Score: a CIBMTR analysis Blood (ASH Annu Meet Abstracts) 116 2010 898
11. M. Jagasia, M. Arora, M. Flowers, N.J. Chao, P.L. McCarthy, and J.H. Antin Risk-factors for acute graft-versus-host disease and survival after hematopoietic cell transplantation from siblings and unrelated donors - An analysis of the CIBMTR Blood (ASH Annu Meet Abstracts) 116 2010 Abstract 897
12. J.S. Miller, E.H. Warren, M.R. van den Brink, J. Ritz, W.D. Shlomchik, and W.J. Murphy NCI first International workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on the biology Underlying Recurrence of Malignant disease following allogeneic HSCT: graft-versus-Tumor/Leukemia Reaction Biol Blood Marrow Transplant 16 2010 565 586
13. S. Milosevic, B. Bachnick, K. Karim, G.W. Bornkamm, K. Witter, and A. Gerbitz Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation Transplantation 90 2010 1030 1035
14. M.C. Pasquini, and Z. Wang Current use and outcome of hematopoietic stem cell transplantation: Part I - CIBMTR Summary Slides CIBMTR Newsl [serial Online] 2009 15 2009 7 11
15. S. Beyth, Z. Borovsky, D. Mevorach, M. Liebergall, Z. Gazit, and H. Aslan Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness Blood 105 2005 2214 2219 (Pubitemid 40731815)
16. C. Herrero, and J.A. Perez-Simon Immunomodulatory effect of mesenchymal stem cells Braz J Med Biol Res 43 2010 425 430
17. N.G. Singer, and A.I. Caplan Mesenchymal stem cells: mechanisms of inflammation Annu Rev Pathol 6 2011 457 478
18. W.T. Tse, J.D. Pendleton, W.M. Beyer, M.C. Egalka, and E.C. Guinan Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation Transplantation 75 2003 389 397 (Pubitemid 36222968)
19. A.E. Aksu, E. Horibe, J. Sacks, R. Ikeguchi, J. Breitinger, and M. Scozio Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats Clin Immunol 127 2008 348 358
20. S. Itakura, S. Asari, J. Rawson, T. Ito, I. Todorov, and C.P. Liu Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat Am J Transplant 7 2007 336 346 (Pubitemid 46096326)
21. M.S. Jeon, H.J. Lim, T.G. Yi, M.W. Im, H.S. Yoo, and J.H. Choi Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex-matched allogeneic graft-versus-host disease mouse model Cell Immunol 261 2010 57 63
22. A. Bartholomew, C. Sturgeon, M. Siatskas, K. Ferrer, K. McIntosh, and S. Patil Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo Exp Hematol 30 2002 42 48 (Pubitemid 34059216)
23. D. Polchert, J. Sobinsky, G. Douglas, M. Kidd, A. Moadsiri, and E. Reina IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease Eur J Immunol 38 2008 1745 1755
24. A.I. Caplan Adult mesenchymal stem cells for tissue engineering versus regenerative medicine J Cell Physiol 213 2007 341 347 (Pubitemid 47509711)
25. A. Hilfiker, C. Kasper, R. Hass, and A. Haverich Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg 2011
26. N.J. Panetta, D.M. Gupta, N. Quarto, and M.T. Longaker Mesenchymal cells for skeletal tissue engineering Panminerva Med 51 2009 25 41
27. N.K. Satija, V.K. Singh, Y.K. Verma, P. Gupta, S. Sharma, and F. Afrin Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine J Cell Mol Med 13 2009 4385 4402
28. M. Di Nicola, C. Carlo-Stella, M. Magni, M. Milanesi, P.D. Longoni, and P. Matteucci Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli Blood 99 2002 3838 3843 (Pubitemid 34534559)
29. S. Aggarwal, and M.F. Pittenger Human mesenchymal stem cells modulate allogeneic immune cell responses Blood 105 2005 1815 1822 (Pubitemid 40223708)
30. E. Dander, G. Lucchini, P. Vinci, M. Introna, S. Bonanomi, and A. Balduzzi Understanding the immunomodulatory effect of mesenchymal stem cell infused in transplanted patients with steroid-refractory GVHD Blood (ASH Annu Meet Abstracts) 116 2010 2306
31. K. Le Blanc, I. Rasmusson, B. Sundberg, C. Gotherstrom, M. Hassan, and M. Uzunel Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Lancet 363 2004 1439 1441 (Pubitemid 38586721)
32. O. Ringden, M. Uzunel, I. Rasmusson, M. Remberger, B. Sundberg, and H. Lonnies Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease Transplantation 81 2006 1390 1397 (Pubitemid 43847148)
33. N. Arima, F. Nakamura, A. Fukunaga, H. Hirata, H. Machida, and S. Kouno Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study Cytotherapy 12 2010 265 268
34. F. Baron, C. Lechanteur, E. Willems, F. Bruck, E. Baudoux, and L. Seidel Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning Biol Blood Marrow Transplant 16 2010 838 847
35. B. Fang, Y.P. Song, L.M. Liao, Q. Han, and R.C. Zhao Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells Bone Marrow Transplant 38 2006 389 390
36. B. Fang, Y. Song, R.C. Zhao, Q. Han, and Q. Lin Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis Transplant Proc 39 2007 1710 1713 (Pubitemid 46907940)
37. B. Fang, Y. Song, Q. Lin, Y. Zhang, Y. Cao, and R.C. Zhao Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children Pediatr Transplant 11 2007 814 817 (Pubitemid 47512333)
38. B. Fang, N. Li, Y. Song, J. Li, R.C. Zhao, and Y. Ma Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia Pediatr Transplant 13 2009 499 502
39. P. Kebriaei, L. Isola, E. Bahceci, K. Holland, S. Rowley, and J. McGuirk Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease Biol Blood Marrow Transplant 15 2009 804 811
40. K. Le Blanc, F. Frassoni, L. Ball, F. Locatelli, H. Roelofs, and I. Lewis Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study Lancet 371 2008 1579 1586 (Pubitemid 351626841)
41. G. Lucchini, M. Introna, E. Dander, A. Rovelli, A. Balduzzi, and S. Bonanomi Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population Biol Blood Marrow Transplant 16 2010 1293 1301
42. I. Muller, S. Kordowich, C. Holzwarth, G. Isensee, P. Lang, and F. Neunhoeffer Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation Blood Cells Mol Dis 40 2008 25 32 (Pubitemid 350199635)
43. M. von Bonin, F. Stolzel, A. Goedecke, K. Richter, N. Wuschek, and K. Holig Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium Bone Marrow Transplant 43 2009 245 251
44. J.Y. Weng, X. Du, S.X. Geng, Y.W. Peng, Z. Wang, and Z.S. Lu Mesenchymal stem cell as salvage treatment for refractory chronic GVHD Bone Marrow Transplant 2010
45. H. Zhou, M. Guo, C. Bian, Z. Sun, Z. Yang, and Y. Zeng Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report Biol Blood Marrow Transplant 16 2010 403 412
46. ®) As A rescue agent for severe treatment resistant GVHD in pediatric patients Biol Blood Marrow Transplant 16 2010 S169
47. P.J. Martin, J.P. Uberti, R.J. Soiffer, H. Klingemann, E.K. Waller, and A.S. Daly Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and Gut: results of A randomized, placebo-controlled, Multicenter phase III trial in GVHD Biol Blood Marrow Transplant 16 2010 S169 S170
48. D. Baksh, R. Yao, and R.S. Tuan Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow Stem Cells 25 2007 1384 1392 (Pubitemid 47106005)
49. R.D. Lund, S. Wang, B. Lu, S. Girman, T. Holmes, and Y. Sauve Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease Stem Cells 25 2007 602 611 (Pubitemid 46354218)
50. L. Wang, I. Tran, K. Seshareddy, M.L. Weiss, and M.S. Detamore A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering Tissue Eng Part A 15 2009 2259 2266
51. K.H. Yoo, I.K. Jang, M.W. Lee, H.E. Kim, M.S. Yang, and Y. Eom Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues Cell Immunol 259 2009 150 156
52. H. Zhang, S. Fazel, H. Tian, D.A. Mickle, R.D. Weisel, and T. Fujii Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy Am J Physiol Heart Circ Physiol 289 2005 H2089 H2096
53. Z.Y. Zhang, S.H. Teoh, M.S. Chong, J.T. Schantz, N.M. Fisk, and M.A. Choolani Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells Stem Cells 27 2009 126 137
54. T. Deuse, M. Stubbendorff, K. Tang-Quan, N. Phillips, M.A. Kay, and T. Eiermann Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells Cell Transplant 2010
55. M. Zeddou, A. Briquet, B. Relic, C. Josse, M.G. Malaise, and A. Gothot The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood Cell Biol Int 34 2010 693 701
56. S.J. Prasanna, D. Gopalakrishnan, S.R. Shankar, and A.B. Vasandan Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially PLoS One 5 2010 e9016
57. M. Najar, G. Raicevic, H.I. Boufker, K.H. Fayyad, B.C. De, and N. Meuleman Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets:Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources Cell Immunol 264 2010 171 179
58. M.L. Weiss, C. Anderson, S. Medicetty, K.B. Seshareddy, R.J. Weiss, and I. VanderWerff Immune properties of human umbilical cord Wharton's jelly-derived cells Stem Cells 26 2008 2865 2874
59. A. Nasef, N. Ashammakhi, and L. Fouillard Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms Regen Med 3 2008 531 546
60. I. Rasmusson Immune modulation by mesenchymal stem cells Exp Cell Res 312 2006 2169 2179 (Pubitemid 43928946)
61. S. Tipnis, C. Viswanathan, and A.S. Majumdar Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO Immunol Cell Biol 88 2010 795 806
62. K. English, J.M. Ryan, L. Tobin, M.J. Murphy, F.P. Barry, and B.P. Mahon Cell contact, prostaglandin E(2) and transforming growth factor beta 1 p.ay non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells Clin Exp Immunol 156 2009 149 160
63. R. Meisel, A. Zibert, M. Laryea, U. Gobel, W. Daubener, and D. Dilloo Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation Blood 103 2004 4619 4621 (Pubitemid 38745993)
64. K. Sato, K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, and T. Nagai Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells Blood 109 2007 228 234 (Pubitemid 46053063)
65. K.C. Chao, K.F. Chao, Y.S. Fu, and S.H. Liu Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes PLoS One 3 2008 e1451
66. P.S. Cho, D.J. Messina, E.L. Hirsh, N. Chi, S.N. Goldman, and D.P. Lo Immunogenicity of umbilical cord tissue derived cells Blood 111 2008 430 438
67. E. Valencic, E. Piscianz, M. Andolina, A. Ventura, and A. Tommasini The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation Cytotherapy 12 2010 154 160